Choline supplementation in children with fetal alcohol spectrum disorders: A randomized, double-blind, placebo-controlled trial

Jeffrey R Wozniak, Anita J. Fuglestad, Judith K Eckerle, Birgit A. Fink, Heather L. Hoecker, Christopher J Boys, Joshua P. Radke, Maria Kroupina, Neely C Miller, Ann M Brearley, Steven H. Zeisel, Michael K Georgieff

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Fetal alcohol spectrum disorders (FASDs) are conditions characterized by physical anomalies, neurodevelopmental abnormalities, and neurocognitive deficits, including intellectual, executive, and memory deficits. There are no specific biological treatments for FASDs, but rodent models have shown that prenatal or postnatal choline supplementation reduces cognitive and behavioral deficits. Potential mechanisms include phospholipid production for axonal growth and myelination, acetylcholine enhancement, and epigenetic effects. Objective: Our primary goal was to determine whether postnatal choline supplementation has the potential to improve neurocognitive functioning, particularly hippocampal-dependent memory, in children with FASDs. Design: The study was a double-blind, randomized, placebocontrolled pilot trial in children (aged 2.5-5 y at enrollment) with FASDs (n = 60) who received 500 mg choline or a placebo daily for 9 mo. Outcome measures were Mullen Scales of Early Learning (primary) and the elicited imitation (EI) memory paradigm (secondary). Results: The administration proved feasible, and choline was well tolerated. Participants received a dose on 88% of enrolled days. The only adverse event linked to choline was a fishy body odor. Choline supplementation improved the secondary outcome (EI) only after immediate recall performance was controlled for, and the outcome was moderated by age. The treatment effect on EI items recalled was significant in the younger participants (2.5- to #4.0-y-olds); the young choline group showed an increase of 12-14 percentage points greater than that of the young placebo group on delayed recall measures during treatment. However, there was a marginal baseline difference in delayed item recall between the young choline and placebo groups as well as a potential ceiling effect for item recall, both of which likely contributed to the observed treatment effect. We also observed a trend toward a negative effect of choline supplementation on the immediate EI recall of ordered pairs; the young placebo group showed an increase of 8-17 percentage points greater than that of the choline group during treatment. There was an inverse relation between choline dose (in mg/kg) and memory improvement (P = 0.041); the data suggest that weight-adjusted doses may be a better alternative to a fixed dose in future studies. Limitations included trend-level baseline differences in performance, the post-hoc determination of age moderation, and potential ceiling effects for the memory measure. Conclusions: This pilot study suggests that an additional evaluation of choline supplementation as an intervention for memory functioning in children with FASDs is warranted. The observed interaction between age and choline's effect on EI suggests that potential sensitive periods should be considered in future work. This trial was registered at clinicaltrials.gov as NCT01149538.

Original languageEnglish (US)
Pages (from-to)1113-1125
Number of pages13
JournalAmerican Journal of Clinical Nutrition
Volume102
Issue number5
DOIs
StatePublished - Nov 1 2015

Fingerprint

Fetal Alcohol Spectrum Disorders
Choline
Placebos
Therapeutics
Memory Disorders
Short-Term Memory
Epigenomics
Acetylcholine

Keywords

  • Children
  • Fetal alcohol spectrum disorder
  • Fetal alcohol syndrome
  • Memory
  • Randomized double-blind placebo-controlled trial

Cite this

Choline supplementation in children with fetal alcohol spectrum disorders : A randomized, double-blind, placebo-controlled trial. / Wozniak, Jeffrey R; Fuglestad, Anita J.; Eckerle, Judith K; Fink, Birgit A.; Hoecker, Heather L.; Boys, Christopher J; Radke, Joshua P.; Kroupina, Maria; Miller, Neely C; Brearley, Ann M; Zeisel, Steven H.; Georgieff, Michael K.

In: American Journal of Clinical Nutrition, Vol. 102, No. 5, 01.11.2015, p. 1113-1125.

Research output: Contribution to journalArticle

@article{85ca76d2bdeb4e869c8f6cc523ba84db,
title = "Choline supplementation in children with fetal alcohol spectrum disorders: A randomized, double-blind, placebo-controlled trial",
abstract = "Background: Fetal alcohol spectrum disorders (FASDs) are conditions characterized by physical anomalies, neurodevelopmental abnormalities, and neurocognitive deficits, including intellectual, executive, and memory deficits. There are no specific biological treatments for FASDs, but rodent models have shown that prenatal or postnatal choline supplementation reduces cognitive and behavioral deficits. Potential mechanisms include phospholipid production for axonal growth and myelination, acetylcholine enhancement, and epigenetic effects. Objective: Our primary goal was to determine whether postnatal choline supplementation has the potential to improve neurocognitive functioning, particularly hippocampal-dependent memory, in children with FASDs. Design: The study was a double-blind, randomized, placebocontrolled pilot trial in children (aged 2.5-5 y at enrollment) with FASDs (n = 60) who received 500 mg choline or a placebo daily for 9 mo. Outcome measures were Mullen Scales of Early Learning (primary) and the elicited imitation (EI) memory paradigm (secondary). Results: The administration proved feasible, and choline was well tolerated. Participants received a dose on 88{\%} of enrolled days. The only adverse event linked to choline was a fishy body odor. Choline supplementation improved the secondary outcome (EI) only after immediate recall performance was controlled for, and the outcome was moderated by age. The treatment effect on EI items recalled was significant in the younger participants (2.5- to #4.0-y-olds); the young choline group showed an increase of 12-14 percentage points greater than that of the young placebo group on delayed recall measures during treatment. However, there was a marginal baseline difference in delayed item recall between the young choline and placebo groups as well as a potential ceiling effect for item recall, both of which likely contributed to the observed treatment effect. We also observed a trend toward a negative effect of choline supplementation on the immediate EI recall of ordered pairs; the young placebo group showed an increase of 8-17 percentage points greater than that of the choline group during treatment. There was an inverse relation between choline dose (in mg/kg) and memory improvement (P = 0.041); the data suggest that weight-adjusted doses may be a better alternative to a fixed dose in future studies. Limitations included trend-level baseline differences in performance, the post-hoc determination of age moderation, and potential ceiling effects for the memory measure. Conclusions: This pilot study suggests that an additional evaluation of choline supplementation as an intervention for memory functioning in children with FASDs is warranted. The observed interaction between age and choline's effect on EI suggests that potential sensitive periods should be considered in future work. This trial was registered at clinicaltrials.gov as NCT01149538.",
keywords = "Children, Fetal alcohol spectrum disorder, Fetal alcohol syndrome, Memory, Randomized double-blind placebo-controlled trial",
author = "Wozniak, {Jeffrey R} and Fuglestad, {Anita J.} and Eckerle, {Judith K} and Fink, {Birgit A.} and Hoecker, {Heather L.} and Boys, {Christopher J} and Radke, {Joshua P.} and Maria Kroupina and Miller, {Neely C} and Brearley, {Ann M} and Zeisel, {Steven H.} and Georgieff, {Michael K}",
year = "2015",
month = "11",
day = "1",
doi = "10.3945/ajcn.114.099168",
language = "English (US)",
volume = "102",
pages = "1113--1125",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "5",

}

TY - JOUR

T1 - Choline supplementation in children with fetal alcohol spectrum disorders

T2 - A randomized, double-blind, placebo-controlled trial

AU - Wozniak, Jeffrey R

AU - Fuglestad, Anita J.

AU - Eckerle, Judith K

AU - Fink, Birgit A.

AU - Hoecker, Heather L.

AU - Boys, Christopher J

AU - Radke, Joshua P.

AU - Kroupina, Maria

AU - Miller, Neely C

AU - Brearley, Ann M

AU - Zeisel, Steven H.

AU - Georgieff, Michael K

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background: Fetal alcohol spectrum disorders (FASDs) are conditions characterized by physical anomalies, neurodevelopmental abnormalities, and neurocognitive deficits, including intellectual, executive, and memory deficits. There are no specific biological treatments for FASDs, but rodent models have shown that prenatal or postnatal choline supplementation reduces cognitive and behavioral deficits. Potential mechanisms include phospholipid production for axonal growth and myelination, acetylcholine enhancement, and epigenetic effects. Objective: Our primary goal was to determine whether postnatal choline supplementation has the potential to improve neurocognitive functioning, particularly hippocampal-dependent memory, in children with FASDs. Design: The study was a double-blind, randomized, placebocontrolled pilot trial in children (aged 2.5-5 y at enrollment) with FASDs (n = 60) who received 500 mg choline or a placebo daily for 9 mo. Outcome measures were Mullen Scales of Early Learning (primary) and the elicited imitation (EI) memory paradigm (secondary). Results: The administration proved feasible, and choline was well tolerated. Participants received a dose on 88% of enrolled days. The only adverse event linked to choline was a fishy body odor. Choline supplementation improved the secondary outcome (EI) only after immediate recall performance was controlled for, and the outcome was moderated by age. The treatment effect on EI items recalled was significant in the younger participants (2.5- to #4.0-y-olds); the young choline group showed an increase of 12-14 percentage points greater than that of the young placebo group on delayed recall measures during treatment. However, there was a marginal baseline difference in delayed item recall between the young choline and placebo groups as well as a potential ceiling effect for item recall, both of which likely contributed to the observed treatment effect. We also observed a trend toward a negative effect of choline supplementation on the immediate EI recall of ordered pairs; the young placebo group showed an increase of 8-17 percentage points greater than that of the choline group during treatment. There was an inverse relation between choline dose (in mg/kg) and memory improvement (P = 0.041); the data suggest that weight-adjusted doses may be a better alternative to a fixed dose in future studies. Limitations included trend-level baseline differences in performance, the post-hoc determination of age moderation, and potential ceiling effects for the memory measure. Conclusions: This pilot study suggests that an additional evaluation of choline supplementation as an intervention for memory functioning in children with FASDs is warranted. The observed interaction between age and choline's effect on EI suggests that potential sensitive periods should be considered in future work. This trial was registered at clinicaltrials.gov as NCT01149538.

AB - Background: Fetal alcohol spectrum disorders (FASDs) are conditions characterized by physical anomalies, neurodevelopmental abnormalities, and neurocognitive deficits, including intellectual, executive, and memory deficits. There are no specific biological treatments for FASDs, but rodent models have shown that prenatal or postnatal choline supplementation reduces cognitive and behavioral deficits. Potential mechanisms include phospholipid production for axonal growth and myelination, acetylcholine enhancement, and epigenetic effects. Objective: Our primary goal was to determine whether postnatal choline supplementation has the potential to improve neurocognitive functioning, particularly hippocampal-dependent memory, in children with FASDs. Design: The study was a double-blind, randomized, placebocontrolled pilot trial in children (aged 2.5-5 y at enrollment) with FASDs (n = 60) who received 500 mg choline or a placebo daily for 9 mo. Outcome measures were Mullen Scales of Early Learning (primary) and the elicited imitation (EI) memory paradigm (secondary). Results: The administration proved feasible, and choline was well tolerated. Participants received a dose on 88% of enrolled days. The only adverse event linked to choline was a fishy body odor. Choline supplementation improved the secondary outcome (EI) only after immediate recall performance was controlled for, and the outcome was moderated by age. The treatment effect on EI items recalled was significant in the younger participants (2.5- to #4.0-y-olds); the young choline group showed an increase of 12-14 percentage points greater than that of the young placebo group on delayed recall measures during treatment. However, there was a marginal baseline difference in delayed item recall between the young choline and placebo groups as well as a potential ceiling effect for item recall, both of which likely contributed to the observed treatment effect. We also observed a trend toward a negative effect of choline supplementation on the immediate EI recall of ordered pairs; the young placebo group showed an increase of 8-17 percentage points greater than that of the choline group during treatment. There was an inverse relation between choline dose (in mg/kg) and memory improvement (P = 0.041); the data suggest that weight-adjusted doses may be a better alternative to a fixed dose in future studies. Limitations included trend-level baseline differences in performance, the post-hoc determination of age moderation, and potential ceiling effects for the memory measure. Conclusions: This pilot study suggests that an additional evaluation of choline supplementation as an intervention for memory functioning in children with FASDs is warranted. The observed interaction between age and choline's effect on EI suggests that potential sensitive periods should be considered in future work. This trial was registered at clinicaltrials.gov as NCT01149538.

KW - Children

KW - Fetal alcohol spectrum disorder

KW - Fetal alcohol syndrome

KW - Memory

KW - Randomized double-blind placebo-controlled trial

UR - http://www.scopus.com/inward/record.url?scp=84946077165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946077165&partnerID=8YFLogxK

U2 - 10.3945/ajcn.114.099168

DO - 10.3945/ajcn.114.099168

M3 - Article

C2 - 26447156

AN - SCOPUS:84946077165

VL - 102

SP - 1113

EP - 1125

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 5

ER -